Mutations of several residues in the MRG-binding region of PALB2 were found in breast cancer patients [13,42,43,44], including Asp616His, Pro615Ser and Pro621Thr mutations (Figure 5A,B). This evidence concerns the gene PALB2 and breast carcinoma.